The interaction of alpha-thalassemia and homozygous sickle-cell disease
Higgs, Douglas R; Aldridge, Beverley E; Lamb, Janette; Clegg, John B; Weatherall, David J; Hayes, Richard J; Grandison, Yvonne G; Lowrie, Yvonne; Mason, Karlene P; Serjeant, Beryl E; Serjeant, Graham R.
N Engl J Med
; 306(24): 1441-6, 1982.
Artículo
en Inglés
| MedCarib | ID: med-14410
Patients with homozygous sickle-cell disease may be homozygous for alpha-thalassemia 2 (O-/O-), may be heterozygous for alpha-thalessemia 2 (O-/OO), or may have a normal alpha-globin-gene complement (OO/OO). We compared the clinical and hematologic features of 44 patients who had sickle-cell disease and homozygous alpha-thalassemia 2 with those of controls with the two hematologic conditions. The patients with homozygous alpha-thalassemia 2 had significantly higher red-cell counts and levels of hemoglobin and hemoglobin Aý, as well as significantly lower hemoglobin F, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, reticulocyte counts, irreversibly-sickled-cell counts, and serum total billirubin levels, than those with a normal alpha-globin-gene complement. Heterozygotes (O-/OO) had intermediate values. In the group with homozygous alpha-thalassemia 2, fewer patients had episodes of acute chest syndrome and chronic leg ulceration and more patients had splenomegaly, as compared with patients in the other two subgroups. These data confirmed previous suggestions that alpha-thalassemia inhibits in vivo sickling in homozygous sickle-cell disease and may be an important genetic determinant of its hematologic severity.
Biblioteca responsable:
JM3.1
Ubicación: JM3.1; R11.N4
Documentos relacionados